Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

Key Who May Qualify: - Male or women of non-child bearing potential - BMI 18.0 to 35.0 - Good overall health deemed by the study Investigator - CHB infection documented at least 12 months prior to screening - HBeAg-negative CHB - Must be virologically suppressed on current NA treatment Key Who Should NOT Join This Trial: - No history of cirrhosis of the liver - No current infections of Hepatitis A, D, and E, human weakened immune system virus (type 1 and 2), and no history of or current hepatitis C. In addition, no other active infections deemed clinically relevant. - No signs of hepatocellular carcinoma - Not received an organ transplant - No malignancy within 5 years of screening, except for specific cancers that are cured by surgical resection (e.g., basal cell skin cancer) - No investigational agent received within 6 months of screening Always talk to your doctor about whether this trial is right for you.